Two COVID-19 treatments that have not yet been authorized for administration were successful in clinical trials, the companies behind the drugs announced on April 11. A pill developed to attack cancer was successful in curbing deaths among COVID-19 patients in hospitals deemed high risk for Acute Respiratory Distress Syndrome, according to U.S.-based Veru Inc., the maker of the drug. The interim results from a Phase 3 double-blind, randomized, placebo-controlled trial, conducted in the United States and five other countries, showed a 55 percent relative reduction in deaths, the company said. Of the 52 patients in the placebo group, 45 percent died. Of the group treated with the pill, known as sabizabulin, 20 percent died. The average age of the patients was in the low 60s, and patients in both groups had the Omicron virus variant, though some were sickened with Delta. “This really represents a big step forward,” Dr. Mitchelle Steiner, …